Hormone-refractory prostate cancer
Not recruitingStudy on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Advanced Prostate Cancer and Different Levels of Kidney Function
Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Advanced Prostate Cancer and Different Levels of Kidney Function
- Disease:Hormone-refractory prostate cancer
- Substances:GozetotideLutetium (177LU) vipivotide tetraxetan
Germany- Participants:18–64 years · 65+ years
- Substances:Gozetotide
- Sponsor:Novartis Pharma AG












